Snyder, Robert W., M.D., Ph.D.

Snyder Biomedical is a clinical-stage biotechnology company dedicated to developing innovative treatments for age-related macular degeneration (AMD) and other blinding eye diseases. The company was founded by Dr. Robert W. Snyder, an ophthalmologist and cell biologist, to commercialize research identifying L-DOPA as the natural ligand for the GPR143 receptor in the eye. By stimulating GPR143, Snyder Biomedical's lead program aims to regulate the secretion of vascular endothelial growth factor (VEGF) and protect retinal pigment epithelium cells. The company has advanced carbidopa-levodopa into Phase 2 clinical trials for both neovascular (wet) and atrophic (dry) AMD. Snyder Biomedical operates in collaboration with the University of Arizona and seeks to provide cost-effective, non-invasive alternatives or adjuncts to current anti-VEGF injection therapies.